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PreviewsIt appears that both Cdk14 and GSK3
can phosphorylate LRP5/6 on S1490,
leading to questions of priority. Do both
kinases phosphorylate LRP5/6 in vivo, or
is one of these kinases the predominant
source of S1490 phosphorylation? LRP5/
6 contains five PPPSP motifs, and David-
sonet al. focusonly on themotif containing
S1490. Therefore, it is possible that Cdk14
does not phosphorylate all five PPPSP
motifs, despite that fact that these do-
mains display similar amino acid se-
quences. In fact, GSK3 could share the
responsibility of phosphorylating certain
specific domains with Cdk14. Another
possibility is that, depending on the envi-
ronment or cell typeorWnt familymember,
eitherCdk14orGSK3couldphosphorylate
the five PPPSP motifs. All these questions
will need to be addressed in the future.
Apart from cyclin D1 and c-myc, Wnt-
based regulation of the cell cycle appears
to occur through microtubule binding,
mediated by Apc, EB1, andGSK3 (Angers
and Moon, 2009; McCartney and Nathke,
2008; Salinas, 2007). This pathway not750 Developmental Cell 17, December 15, 20only affects the cytoskeleton and polarity,
but it also affects spindle alignment,
spindle position, and the mitotic spindle
checkpoint. The coupling of Wnt signaling
and mitosis at the level of LRP5/6
phosphorylation is a novel and intriguing
concept. Obviously, it is rather unlikely
that only mitotic cells are susceptible to
Wnt signaling. It is more likely that the
efficiency of Wnt signaling is increased
in mitosis. At the moment, it is not clear
why Wnt signaling should be more
efficient in mitosis, a phase when many
processes cease due to the cell dividing.
For example, transcription is reduced to
very low levels during mitosis, although
transcriptional readouts of Wnt signaling
seem to peak during this phase. The
current study suggests that Wnt signaling
promotes proliferation not only through
cyclin D1 and c-myc in G1/S phase,
but also during mitosis via unknown
targets. As we adjust to this novel con-
cept, the broader implications on both
mitosis and Wnt signaling will have to be
considered.09 ª2009 Elsevier Inc.REFERENCES
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Moellering et al. recently reported that a cell-permeable ‘‘stapled’’ synthetic peptide of the Notch coactivator
Mastermind is a potent dominant-negative inhibitor of oncogenic Notch signaling in T cell acute lympho-
blastic leukemia. This new class of inhibitor may find broad utility in blocking protein-protein interactions
that underlie many human diseases.TheNotch signaling pathway is transiently
induced during development to control
cell proliferation and differentiation (Aster
et al., 2008). In this pathway, binding
of extracellular ligands to the Notch1
receptor causes the proteolytic cleavage
and release of the Notch1 intracellular
domain (NICD). The short-lived NICD
protein translocates to the nucleus, where
it binds to Suppressor of Hairless [Su(H)]
CSL DNA-binding proteins to activate
downstream target genes (Figure 1).Loss of the normal cellular restraints on
Notch receptor processing and NICD
stability in the nucleus leads to an inappro-
priate reactivation in Notch signaling in
T cell acute lymphoblastic leukemia
(T-ALL) and several other cancers. Notch
signaling can be inhibited by chemical
inhibitorsof thegamma-secretasecomplex
(GSIs), which cleave the Notch1 receptor;
however, chronic disruption of Notch
signalingcombinedwithoff-targetactivities
have limited thepotential therapeuticuseofthese compounds and prompted a search
formore selective inhibitors of the pathway.
A different approach was suggested
from high-resolution structures of the
Notch enhancer complex, which revealed
a novel shallow groove that is created
upon binding of NICD to CSL (Nam
et al., 2006). This shared interface creates
a cavity that recruits Mastermind-like
(MAML) coactivators (Saint Just Ribeiro
and Wallberg, 2009) to the enhancer
complex. A 62 amino acid (aa) a-helical
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Figure 1. Diagram of MAML1 versus SAHM1 Binding
(A) The Mastermind-like 1 (MAML1) coactivator binds to the preformed NICD:CSL DNA-binding protein
complex to activate Notch target genes.
(B) A synthetic stapled 16aaMAML1 peptide (SAHM1, shown in brown) binds to the preformed NICD:CSL
complex and blocks recruitment of MAML1 to the Notch enhancer complex. This prevents the expression
of MAML1-dependent oncogenic Notch target genes, such as HES1 and MYC, which are necessary for
growth of T cell acute lymphoblastic leukemia cells.
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Previewsfragment of MAML1 (aa 13–74) precisely
fits into this groove. The Bradner lab and
colleagues reasoned that a hydrocarbon-
stapled (stabilized) peptide mimetic might
serve as a dominant-negative inhibitor of
Notch signaling by binding to the NICD:
CSL enhancer complex and blocking
recruitment of endogenous MAML1. After
probing this surface with multiple syn-
thetic peptides, Moellering et al. (2009)
selected a 16aa peptide (designated
SAHM1; aa 21–36) that bound tightly (Kd,
0.12 ± 0.02 mM) to the NICD:CSL complex
in vitro. Exposure of cells to 20 mMSAHM1
peptide significantly reduced transcrip-
tion ofHES1,MYC, and other Notch target
genes, whereas various mutant peptides
were relatively inactive.
Transcription profiling studies estab-
lished that known Notch targets were
among those most severely downregu-lated by SAHM1, which also included
downstream target genes of two Notch-
induced activators, c-Myc and E2F1. A
noninvasive bioluminescent cell imaging
approach was used to measure the ability
of SAHM1 to impede the progression of
established leukemia in a mouse model
of the disease. Twice-daily intraperitoneal
SAHM1 injections led to a dose-depen-
dent regression of tumors in these mice,
accompanied by reduced transcription
of the HES1 and MYC genes, indicating
that the Notch signaling pathway is a
major target of SAHM1 in T-ALL leukemic
cells in vivo.
Taken together, these new findings
provide exciting evidence that stabilized,
cell-permeable peptides can effectively
disrupt complex protein assemblies
in vivo. Unlike inhibitors that inactivate
kinases or other enzymes, this strategyDevelopmental Cell 17, Daims for greater specificity by interfering
withasingledomainofa regulatoryprotein.
But how specific is SAHM1 inhibition?
Although SAHM1 was found to affect a
similar set of genes to GSIs, it may ulti-
mately prove tobemore selective because
MAML1 is not universally required for
Notch transactivation. Previous studies
have shown that MAML1 acts preferen-
tially at promoters containing tandem
inverted repeat Su(H)/CSL DNA-binding
sites (so-called ‘‘paired’’ CSL sequences;
Figure 1), and can act synergistically with
nearby basic Helix-loop-helix activators.
Even within this subset of Notch target
genes, MAML1 has been suggested to
function in a promoter-specific manner
(Cave and Caudy, 2008). Consequently,
the SAHM1 peptide might target only a
subset of Notch target genes, which
fortuitously includes some of the most
oncogenic of the Notch-induced genes.
Viewed in this context, SAHM1 may func-
tion more selectively than GSIs, which
should downregulate all Notch-dependent
genes.
On the other hand, the SAHM1 peptide
might have unintended consequences
on other signaling pathways, because
MAML1 does not function exclusively in
Notch signaling. Emerging studies indi-
cate that MAML1 is also an important
coactivator for beta-catenin, p53, and the
muscle-specificMEF2Cprotein (Saint Just
Ribeiro and Wallberg, 2009). Mastermind
proteins bind extensively to Drosophila
polytene chromosomes, including the
ecdysone-induced puffs, further suggest-
ing a widespread role in gene expres-
sion. Mastermind binds tightly to the p300
histone acetyltransferase (HAT) and can
recruit it to active genes. However, the
order of Notch enhancer complex
assembly in vivo is not firmly established,
and histone acetylation has also been
shown to promote or stabilize binding of
Notch enhancer complexes to their tar-
get genes in vivo (Krejcı´ and Bray, 2007).
Similarly, the binding of Mastermind to
polytene chromosomes is lost in mutants
of the Drosophila TRRAP/Tra1 protein, a
critical component of several HAT com-
plexes (Gauseetal., 2006). Together, these
data indicate that histone acetylation
may play roles in both recruiting and
activating Notch enhancer complexes on
chromatin.
Interestingly, expression of MAML1
strongly upregulatesp300catalytic activityecember 15, 2009 ª2009 Elsevier Inc. 751
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Previewsin vivo, and forms large nuclear foci con-
taining p300 and acetylated histones
(Saint Just Ribeiro and Wallberg, 2009).
MAML1 also interacts directly with CDK8,
which, likeMAML1, is required for transac-
tivation by p53 (Donner et al., 2007) and
beta-catenin (Firestein and Hahn, 2009).
Coexpression of MAML1 with NICD and
CSL proteins in cells induces proteolytic
destruction of NICD, indicating that it
might also help in the disassembly of the
enhancer complex following signaling.
Thus MAML1 may serve as a scaffold to
integrate the activities of multiple enzy-
matic complexes in transcription.
The various activities of the Master-
mind-like coactivators illustrate the great
utility of the approach used by Moellering
et al. (2009). Whereas transcription would
be affected broadly by targeted elimina-
tion of MAML1 or chemical inhibiton of
p300 or CDK8, themore selective SAHM1
peptide may simply uncouple MAML1
from the Notch pathway while leaving its
other activities intact. A central question
then is whether the SAHM1 peptide might752 Developmental Cell 17, December 15, 20also block binding of MAML1 to p53,
beta-catenin, or other activators. SAHM1
might be expected to also block growth
of colon cancer cells, which depends
upon Notch as well as Wnt/beta-catenin
signaling (van Es et al., 2005). However,
the utility of this peptide could be com-
promised if it is found to disrupt trans-
cription by p53 or other tumor suppres-
sors. Therefore to better appreciate the
potential therapeutic utility of SAHM1
peptides, it will be important to define
how MAML1 functions in other signaling
pathways.
These new findings from Bradner and
colleagues provide an important ‘‘proof
of principle’’ that effective domain-selec-
tive disruption of regulatory protein inter-
actions is achievable both in cells and in
animals. Looking forward, this elegant
new technology could be used to block
other critical developmental and cancer
signaling pathways, or to inhibit viral
proteins that selectively engage host cell
factors to promote virus replication in
infectious diseases or cancer.09 ª2009 Elsevier Inc.REFERENCES
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In this issue of Developmental Cell, Suizu et al. (2009) describe a new mechanism for posttranslational
regulation of the Akt serine/threonine protein kinase involving ubiquitination. They show that the E3 ubiquitin
ligase TTC3 modifies phosphorylated and activated Akt and thereby promotes its degradation by the
proteasome in the nucleus.The phosphoinositide 3-kinase (PI3K) and
Akt (also known as protein kinase B [PKB])
signaling pathway controls a variety of
cellular phenotypes. Somatic mutations
in multiple enzymes in the PI3K signaling
cascade have been linked to a variety of
human pathophysiological conditions,
most notably cancer (Engelman, 2009).
At this point, multiple phase I and phase
II clinical trials are underway with small
molecule inhibitors targeting one or more
enzymes in the pathway. In their study,
Suizu et al. (2009) uncover a new facetof Akt regulation and reveal a mechanism
for termination of Akt signaling in the
nucleus that is mediated by the E3 ubiqui-
tin ligase TTC3.
The basic mechanism of Akt activation
in response to growth factor stimulation is
well understood. The first and rate-limiting
step is translocation to the membrane,
where Akt directly binds to the PI3K lipid
PtdIns-3,4,5-P3. A conformational change
exposes two residues, Thr308 in the acti-
vation loop, which is phosphorylated by
the phosphoinositide-dependent kinase1 (PDK-1), and carboxyl-terminal Ser473,
which is phosphorylated by the mamma-
lian target of rapamycin complex 2
(mTORC2) (Figure 1). Once phosphory-
lated, activated Akt translocates to
multiple intracellular locations, including
the nucleus. Over 130 substrates of Akt
have been identified that transduce the
signal to a variety of cellular responses
(Manning andCantley, 2007). The defining
feature of Akt-mediated phosphorylation
is a consensus motif on substrates com-
prising Arg-X-Arg-X-X-Ser/Thr, where X
